Dr. Dinesh S. Patel
Ph.D., CChem., FRSC (Lon.)
MANAGING DIRECTOR & CEO

THEMIS
MEDICARE

TML: CS: 2013-14:

10th February, 2014

The Vice President
Listing Department,
National Stock Exchange of India Ltd.
"Exchange Plaza", Bandra – Kurla Complex,
Bandra – East,
Mumbai- 400 051.

Kind Attn: Mr. Hari K.

Dear Sir/Madam

Sub: Unaudited Financial results for the quarter ended 31st December, 2013.

The Board of Directors at it's meeting held today, considered and approved Unaudited Financial Results for the quarter ended 31st December, 2013 together with Limited Review Report by Statutory Auditors of the Company thereon which were earlier approved by the Audit Committee of the Company at it's meeting held before the Board Meeting.

A copy of Unaudited Financial Results for the quarter ended 31st December, 2013 is enclosed for your perusal.

Further, the Board appointed Mr. Hari Subramaniam as Additional Director on the Board w.e.f. 10.02.2014. Mr. Subramanium is a noted Patent Attorney & has rich background of legal field.

This may be taken as compliance of the Listing Agreement; the Company has entered with your stock exchange.

Kindly acknowledge.

Thanking you,

Yours faithfully,
For **THEMIS MEDICARE LTD.**

DR.DINESH S.PATEL
MANAGING DIRECTOR & CEO

M. T. ANKLESHWARIA & CO.
CHARTEREDACCOUNTANTS
MADHU T. ANKLESHWARIA
B.COM. (HONS) F.C.A.

TEL: 2614 9392
7 GOKUL NIWAS,
47, BAJAJ ROAD,
VILE PARLE (WEST),
MUMBAI - 400 056.

The Board of Directors,
Themis Medicare Limited,
Mumbai.

Dear Sirs,

Re: LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS OF THEMIS MEDICARE LTD FOR THE QUARTER ENDED 31st DECEMBER, 2013.

1. INTRODUCTION

We have reviewed the accompanying statement of unaudited financial results of the Themis Medicare Limited, for the quarter ended on 31st December, 2013 except for the disclosures regarding public shareholding and Promoter and Promoter Group Shareholding which have been traced from disclosures made by the management but have neither been reviewed nor been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors at the meeting held on 10-02-2014. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to issue a conclusion on these interim financial statements based on our review.

2. SCOPE OF REVIEW

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

M. T. ANKLESHWARIA & CO. MUMBAI. CHARTERED ACCOUNTANTS

3. CONCLUSION

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.



For **M.T.ANKLESHWARIA & CO,**
CHARTERED ACCOUNTANTS

MADHU T. ANKLESHWARIA

PROPRIETOR


Place: Mumbai
Date: 10.02.2014


THEMIS MEDICARE LTD

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat.
Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

PART I (₹ in Lakhs)
Statement of Unaudited Financial Results for the quarter ended 31st December 2013.

	Particulars	3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Year to date figures for the current period	Year to date figures for the previous period	Previous year ended
		(31/12/2013)	(30/09/2013)	(31/12/2012)	(31/12/2013)	(31/12/2012)	(31/03/2013)
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from operations						
	(a) Net sales/income from operations (Net of excise duty)	3,116.99	5,525.79	3,435.64	13,615.02	12,094.40	14,393.30
	(b) Other operating income	316.00	44.46	46.55	428.89	199.29	432.36
	Total income from operations (net)	3,432.99	5,570.25	3,482.19	14,043.91	12,293.69	14,825.66
2	Expenses						
	(a) Cost of materials consumed	1,219.65	2,273.98	1,632.57	5,708.77	6,535.17	7,812.36
	(b) Purchases of stock-in-trade	176.54	198.66	204.78	1,111.96	419.15	447.08
	(c) Changes in inventories of finished goods,						
	work-in-progress and stock-in-trade	192.78	205.74	99.91	127.93	(389.64)	(947.61)
	(d) Employee benefits expense	680.93	739.09	584.56	2,059.96	1,728.22	2,398.05
	(e) Depreciation and amortisation expense	150.41	148.87	145.62	442.40	432.01	574.61
	(f) Other expenses(Any item exceeding 10% of the total	1,003.02	1,230.00	961.33	3,435.63	3,166.85	4,196.00
	expenses relating to continuing operations to be shown separately)						
	Total expenses	3,423.33	4,796.34	3,628.77	12,886.65	11,891.76	14,480.49
3	Profit / (Loss) from operations before other						
	income, finance costs and exceptional items (1-2)	9.66	773.91	(146.58)	1,157.26	401.93	345.17
4	Other income	80.28	5.00	13.02	166.32	341.64	323.90
5	Profit / (Loss) from ordinary activities before						
	finance costs and exceptional items (3 + 4)	89.94	778.91	(133.56)	1,323.58	743.57	669.07
6	Finance costs	370.11	420.93	277.66	1,186.34	1,154.65	1,520.75
7	Profit / (Loss) from ordinary activities after						
	finance costs but before exceptional items (5 + 6)	(280.17)	357.98	(411.22)	137.24	(411.08)	(851.68)
8	Exceptional items	-	-	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(280.17)	357.98	(411.22)	137.24	(411.08)	(851.68)
10	Tax expense	-	-	(9.73)	(9.72)	(29.30)	(39.06)
11	Net Profit / (Loss) from ordinary activities after tax (9 - 10)	(280.17)	357.98	(401.49)	146.96	(381.78)	(812.62)
12	Extraordinary items (net of tax expense Rs. NIL)	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 + 12)	(280.17)	357.98	(401.49)	146.96	(381.78)	(812.62)
14	Share of profit / (loss) of associates	-	-	-	-	-	-
15	Minority interest	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit						
	/(loss) of associates (13+14 +15).	(280.17)	357.98	(401.49)	146.96	(381.78)	(812.62)
17	Paid-up equity share capital- Face Value Rs. 10/- each	805.05	805.05	805.05	805.05	805.05	805.05
18	Reserve excluding Revaluation Reserves as per balance sheet of						3,558.04
	previous accounting year						
19	Earnings per share (before extraordinary items)						
	(a) Basic	(3.48)	4.45	(4.99)	1.83	(4.74)	(10.09)
	(b) Diluted	(3.17)	4.04	(4.75)	1.66	(4.52)	(9.18)
19ii	Earnings per share (after extraordinary items)						
	(a) Basic	(3.48)	4.45	(4.99)	1.83	(4.74)	(10.09)
	(b) Diluted	(3.17)	4.04	(4.75)	1.66	(4.52)	(9.18)





PART II

(₹ in Lakhs)

Information for the quarter ended 31/12/2013

	Particulars	3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Year to date figures for the current period	Year to date figures for the previous period	Previous year ended
		(31/12/2013)	(30/09/2013)	(31/12/2012)	(31/12/2013)	(31/12/2012)	(31/03/2013)
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	- Number of shares	2395405	2423975	2439685	2395405	2439685	2439685
	- Percentage of shareholding	29.75	30.11	30.30	29.75	30.30	30.30
2	Promoters and Promoter Group Shareholding						
	a) Pledged / Encumbered						
	- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total						
	shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total						
	share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non - encumbered						
	- Number of shares	5655095	5626525	5610815	5655095	5610815	5610815
	- Percentage of shares (as a % of the total						
	shareholding of the Promoter and						
	Promoter group)	100	100	100	100	100	100
	- Percentage of shares (as a % of the total						
	share capital of the company)	70.25	69.89	69.70	70.25	69.70	69.70

	Particulars	3 months ended (31/12/2013)
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	-
	Received during the quarter	2
	Disposed of during the quarter	2
	Remaining unresolved at the end of the quarter	-

NOTES :

1.) The Company has only one segment namely pharmaceuticals, hence no separate segmentwise disclosure has been made.
2.) 4,00,000 fully convertible preferential warrants issued to some of the promoters during the year 2012-13 are converted into Equity Shares on 15.01.2014. Effect of the same is not given in the current quarter.
3.) The above results were reviewed by the Audit Committee and aproved by the Board of Directors at its meeting held on 10th February, 2014.

M. T. ANKLESHWARIA & CO. CHARTERED ACCOUNTANTS M No. 36128 MUMBAI.

As per Review Report attached
For M. T. Ankleshwaria & Co.
Chartered Accountants

Madhu T. Ankleshwaria
Proprietor

By Order of the Board
For THEMIS MEDICARE LTD

Dr. DINESH PATEL
(Managing Director & CEO)

Place : Mumbai
Date : 10 / 02 /2014